Department of Urology, Peking University First Hospital, Beijing, P.R. China.
Institute of Urology, Peking University, Beijing, P.R. China.
Genet Med. 2018 Oct;20(10):1266-1273. doi: 10.1038/gim.2017.261. Epub 2018 Mar 29.
Von Hippel-Lindau (VHL) disease is a rare hereditary cancer syndrome that reduces life expectancy. We aimed to construct a more valuable genotype-phenotype correlation based on alterations in VHL protein (pVHL).
VHL patients (n = 339) were recruited and grouped based on mutation types: HIF-α binding site missense (HM) mutations, non-HIF-α binding site missense (nHM) mutations, and truncating (TR) mutations. Age-related risks of VHL-associated tumors and patient survival were compared.
Missense mutations conferred an increased risk of pheochromocytoma (HR = 1.854, p = 0.047) compared with truncating mutations. The risk of pheochromocytoma was lower in the HM group than in the nHM group (HR = 0.298, p = 0.003) but was similar between HM and TR groups (HR = 0.901, p = 0.810). Patients in the nHM group had a higher risk of pheochromocytoma (HR = 3.447, p < 0.001) and lower risks of central nervous system hemangioblastoma (CHB) (HR = 0.700, p = 0.045), renal cell carcinoma (HR = 0.610, p = 0.024), and pancreatic tumor (HR = 0.382, p < 0.001) than those in the combined HM and TR (HMTR) group. Moreover, nHM mutations were independently associated with better overall survival (HR = 0.345, p = 0.005) and CHB-specific survival (HR = 0.129, p = 0.005) than HMTR mutations.
The modified genotype-phenotype correlation links VHL gene mutation, substrate binding site, and phenotypic diversity (penetrance and survival), and provides more accurate information for genetic counseling and pathogenesis studies.
希佩尔-林道(VHL)病是一种罕见的遗传性癌症综合征,会降低预期寿命。我们旨在基于 VHL 蛋白(pVHL)的改变构建更有价值的基因型-表型相关性。
招募了 339 名 VHL 患者,并根据突变类型进行分组:HIF-α 结合位点错义(HM)突变、非 HIF-α 结合位点错义(nHM)突变和截断(TR)突变。比较了 VHL 相关肿瘤的年龄相关风险和患者生存情况。
与截断突变相比,错义突变使嗜铬细胞瘤(HR=1.854,p=0.047)的风险增加。HM 组的嗜铬细胞瘤风险低于 nHM 组(HR=0.298,p=0.003),但与 TR 组相似(HR=0.901,p=0.810)。nHM 组患者的嗜铬细胞瘤风险更高(HR=3.447,p<0.001),中枢神经系统血管母细胞瘤(CHB)(HR=0.700,p=0.045)、肾细胞癌(HR=0.610,p=0.024)和胰腺肿瘤(HR=0.382,p<0.001)的风险较低,与 HMTR 组相比。此外,nHM 突变与总体生存(HR=0.345,p=0.005)和 CHB 特异性生存(HR=0.129,p=0.005)独立相关,优于 HMTR 突变。
改良的基因型-表型相关性将 VHL 基因突变、底物结合位点和表型多样性(外显率和生存)联系起来,为遗传咨询和发病机制研究提供了更准确的信息。